Login
$MLTX
$11.73 +$0.00 (0.0%) After hours

$MLTX SEC Filings

Filed On Filing
04 Nov 2026 10-Q
04 Nov 2026 8-K: Results of Operations and Financial Condition

ZUG, Switzerland, November 4, 2026 – MoonLake Immunotherapeutics (NASDAQ: MLTX) ("MoonLake" or the "Company"), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today provided a bu...

30 Sep 2026 8-K: Other Events

On September 30, 2026, MoonLake Immunotherapeutics (the “Company”) submitted a Biologics License Application (“BLA”) to the U.S. Food and Drug Administration (“FDA”), seeking approval of its tri-specific nanobody sonelokimab for the trea...

14 Aug 2026 SCHEDULE 13G/A
14 Aug 2026 SCHEDULE 13G
14 Aug 2026 SCHEDULE 13G/A
10 Aug 2026 REGISTRATION STATEMENT
10 Aug 2026 REGISTRATION STATEMENT
10 Aug 2026 10-Q
10 Aug 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results

29 Jul 2026 Form 4: Reich Kristian, Chief Scientific Officer

Sold 1,100 shares ($22K)

23 Jul 2026 Form 4: Reich Kristian, Chief Scientific Officer

Sold 50,000 shares ($1M) · Sold 2,448 shares ($49K)

21 Jul 2026 Form 4: Reich Kristian, Chief Scientific Officer

Sold 43,700 shares ($878K)

20 Jul 2026 Form 4: Reich Kristian, Chief Scientific Officer

Sold 16,105 shares ($322K)

15 Jul 2026 144
15 Jul 2026 8-K: Other Events

On July 10, 2026, the underwriters of the previously announced public offering of Class A ordinary shares, par value $0.0001 per share (the “Ordinary Shares”), of MoonLake Immunotherapeutics (the “Company”) and, in lieu of Ordinary Share...

13 Jul 2026 Form 4: Santos da Silva Jorge, Director

Sold 33,936 shares ($679K) · Sold 68,289 shares ($1.37M)

02 Jul 2026 Form 4: Santos da Silva Jorge, Director

Sold 47,775 shares ($957K)

30 Jun 2026 144
29 Jun 2026 SCHEDULE 13D/A

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support